A Multicenter, Randomized Controlled Phase II Study of Short-Course Radiotherapy Followed by Sequential PD-1 Inhibitor and FOLFOX Chemotherapy Versus Long-Course Chemoradiotherapy for High-Risk Locally Advanced pMMR/MSS Lower Rectal Adenocarcinoma (STAR Trial)

NCT07669220 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

76

Enrollment

OTHER

Sponsor class

Conditions

Rectal Adenocarcinoma
High-risk Locally Advanced
Short-course Radiotherapy (SCRT)
Immunotherapy
FOLFOX

Interventions

RADIATION: Short-course Radiotherapy, SCRT
DRUG: Toripalimab

Sponsor

Sixth Affiliated Hospital, Sun Yat-sen University

Collaborators

[object Object]